Sky Capital

Skyline Therapeutics is a clinical-stage gene therapy company focused on developing innovative treatments for life-threatening and debilitating diseases. The company leverages its proprietary Adeno-Associated Virus (AAV) platform to design and manufacture next-generation gene therapies with improved efficacy and safety profiles. Its primary focus is on ophthalmic conditions, including neovascular age-related macular degeneration and geographic atrophy, while also exploring applications in rare genetic disorders. Skyline maintains integrated capabilities across research, clinical development, and large-scale GMP manufacturing to accelerate the delivery of transformative medicines to patients globally.